J
Jennifer G. Robinson
Researcher at University of Iowa
Publications - 336
Citations - 38647
Jennifer G. Robinson is an academic researcher from University of Iowa. The author has contributed to research in topics: Women's Health Initiative & Statin. The author has an hindex of 71, co-authored 330 publications receiving 33270 citations. Previous affiliations of Jennifer G. Robinson include Roy J. and Lucille A. Carver College of Medicine & University of Minnesota.
Papers
More filters
Journal ArticleDOI
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone,Jennifer G. Robinson,Alice H. Lichtenstein,C. Noel Bairey Merz,Conrad B. Blum,Robert H. Eckel,Anne C. Goldberg,David Lee Gordon,Daniel Levy,Donald M. Lloyd-Jones,Patrick E. McBride,J. Sanford Schwartz,Susan T. Shero,Sidney C. Smith,Karol E. Watson,Peter W.F. Wilson +15 more
TL;DR: Preamble and Transition to ACC/AHA Guidelines to Reduce Cardiovascular Risk S2 The goals of the …
Journal ArticleDOI
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
David C. Goff,Donald M. Lloyd-Jones,Glen C. Bennett,Sean Coady,Ralph B. D'Agostino,Raymond J. Gibbons,Philip Greenland,Daniel T. Lackland,Daniel Levy,Christopher J. O'Donnell,Jennifer G. Robinson,J. Sanford Schwartz,Susan T. Shero,Sidney C. Smith,Paul D. Sorlie,Neil J. Stone,Peter W.F. Wilson +16 more
TL;DR: Harmon S. Jordan, ScD, Lev Nevo, MD, Janusz Wnek, PhD Jeffrey L. Anderson,MD, FACC, FAHA, Chair-Elect, Nancy M. Halperin, PhD.
Journal ArticleDOI
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
David C. Goff,Donald M. Lloyd-Jones,Faha Glen Bennett,Sean Coady,Jennifer G. Robinson,J. Sanford Schwartz,Raymond J. Gibbons,Susan T. Shero,Philip Greenland,Sidney C. Smith,Daniel T. Lackland,Paul D. Sorlie,Daniel Levy,Neil J. Stone +13 more
TL;DR: The ACC and AHA have collaborated with the National Heart, Lung, and Blood Institute and stakeholder and professional organizations to develop guidelines, standards, and policies that promote optimal patient care and cardiovascular health.
Journal ArticleDOI
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson,Michel Farnier,Michel Krempf,Jean Bergeron,Gérald Luc,Maurizio Averna,Erik S.G. Stroes,Gisle Langslet,Frederick J. Raal,Mahfouz El Shahawy,Michael J. Koren,Norman E. Lepor,Christelle Lorenzato,Robert Pordy,Umesh Chaudhari,John J.P. Kastelein +15 more
TL;DR: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels and there was evidence of a reduction in the rate of cardiovascular events.
Journal ArticleDOI
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Daniel I. Swerdlow,Michael V. Holmes,Karoline Kuchenbaecker,Engmann Jel.,Tina Shah,Reecha Sofat,Yiran Guo,C Chung,Anne Peasey,Roman Pfister,Simon P. Mooijaart,Helen Ireland,Maarten Leusink,Claudia Langenberg,KaWah Li,Jutta Palmen,Phil Howard,Jackie A. Cooper,Fotios Drenos,John Hardy,Mike A. Nalls,Yun Li,Gordon D.O. Lowe,Marlene C. W. Stewart,S. J. Bielinski,Julian Peto,Nicholas J. Timpson,John Gallacher,Malcolm G. Dunlop,Richard S. Houlston,Ian Tomlinson,Ioanna Tzoulaki,Jian'an Luan,Boer Jma.,Nita G. Forouhi,N. C. Onland-Moret,Y. T. van der Schouw,Renate B. Schnabel,Jaroslav A. Hubacek,Růžena Kubínová,Migle Baceviciene,Abdonas Tamosiunas,Andrzej Pajak,Roman Topor-Madry,Sofia Malyutina,Damiano Baldassarre,Bengt Sennblad,Elena Tremoli,U de Faire,Luigi Ferrucci,S Bandenelli,Tetsu Tanaka,James F. Meschia,AB Singleton,Gerjan Navis,I. Mateo Leach,Bakker Sjl.,Ron T. Gansevoort,Ian Ford,Stephen E. Epstein,Mary-Susan Burnett,Joe Devaney,Johan Wouter Jukema,Westendorp Rgj.,G Jan de Borst,Y. van der Graaf,P A de Jong,Mailand-van der Zee A-H.,Olaf H. Klungel,A. de Boer,P. A. Doevendans,Jeffrey W. Stephens,Charles B. Eaton,Jennifer G. Robinson,JoAnn E. Manson,F G Fowkes,Timothy M. Frayling,Jenna Price,Peter H. Whincup,Richard W Morris,Debbie A Lawlor,George Davey Smith,Yoav Ben-Shlomo,Susan Redline,Leslie A. Lange,Meena Kumari,Nicholas J. Wareham,Verschuren Wmm.,Emelia J. Benjamin,John C. Whittaker,Anders Hamsten,Frank Dudbridge,Delaney Jac.,Andrew Wong,Diana Kuh,Rebecca Hardy,Berta Almoguera Castillo,John Connolly,P. van der Harst,Eric J. Brunner,Michael Marmot,Christina L. Wassel,Steve E. Humphries,P.J. Talmud,Mika Kivimäki,Folkert W. Asselbergs,Mikhail I. Voevoda,Martin Bobak,Hynek Pikhart,James G. Wilson,Hakon Hakonarson,Alexander P. Reiner,Brendan J. Keating,Naveed Sattar,Aroon D. Hingorani,Juan P. Casas +115 more
TL;DR: IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials and could help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses.